Wet Macular Degeneration: all 93 studies
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- LEAP Strategy for Neovascular Age-Related Macular DegenerationNot yet recruitingNCT07744204Not applicable
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)RecruitingNCT07496567Phase 2/3
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)RecruitingNCT07440225Phase 2/3
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationRecruitingNCT07064759Phase 3
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationRecruitingNCT05197270Phase 1/2
- Treatment of Neovascular AMD: Artificial Intelligence in Real-world SettingRecruitingNCT05093374Phase 4
- Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).RecruitingNCT04663750Phase 3
- MMP-9 Inhibition for Recalcitrant Wet AMDRecruitingNCT04504123Phase 2
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyEnrolling by invitationNCT03999801Phase 2
- Stem Cell Ophthalmology Treatment Study IIRecruitingNCT03011541Not applicable
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT06190093Phase 3Results posted
- Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT05269966Phase 4Results posted
- Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
- OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)TerminatedNCT04757636Phase 3Results posted
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
- An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
- A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersCompletedNCT04516278Phase 3Results posted
- Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.TerminatedNCT04049266Phase 2/3Results posted
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04047472Phase 3Results posted
- Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
- Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMDCompletedNCT03954626Phase 3Results posted
- Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
- A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)CompletedNCT03861234Phase 1/2Results posted
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03834753Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)CompletedNCT03823300Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)CompletedNCT03823287Phase 3Results posted
- Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT03452527Phase 2Results posted
- Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular DegenerationCompletedNCT03034772Phase 2/3Results posted
- The IAI-OCTA Study; a Study of OCT-Angiography Analysis EfficacyCompletedNCT03022292Phase 4Results posted
- EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept InjectionCompletedNCT02689518Phase 4Results posted
- Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.CompletedNCT02571972Phase 2Results posted
- Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular DegenerationCompletedNCT02305238Phase 4Results posted
- Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMDCompletedNCT02161575Phase 4Results posted
- Aflibercept After Ranibizumab in Exudative Age-related Macular DegenerationCompletedNCT02157077Phase 3Results posted
- A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular DegenerationCompletedNCT02121522Phase 2Results posted
- Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)CompletedNCT01775124Phase 4Results posted
- Pilot Study of X-82 in Patients With Wet AMDCompletedNCT01674569Phase 1/2Results posted
- Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to AfliberceptCompletedNCT01617148Phase 4Results posted
- Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular DegenerationCompletedNCT00517010Early Phase 1Results posted
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationActive, not recruitingNCT06864988Phase 3
- NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular DegenerationActive, not recruitingNCT05984927Phase 1/2
- Artificial Intelligence Diagnostic AidStatus unknownNCT05675540
- A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT05637255Phase 2
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Active, not recruitingNCT05536973Phase 2
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 3
- M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMDCompletedNCT05324150
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationCompletedNCT05230537Phase 2
- Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD RelapseCompletedNCT05211804
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersActive, not recruitingNCT05112861Phase 3
- Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular DegenerationTerminatedNCT05038371
- Reading Speed Improvements in Wet-AMD Patients After Ranibizumab TreatmentCompletedNCT04982484
- RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT04832724Phase 2
- Study of Nutritional Supplementation in Patients With Unilateral Wet AMDCompletedNCT04756310Not applicable
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/3
- Brolucizumab vs. Aflibercept for Retinal Angiomatous ProliferationWithdrawnNCT04698850Phase 4
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active, not recruitingNCT04645212
- Prediction of Progression of Age-Related Macular DegenerationStatus unknownNCT04640649Not applicable
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema PatientsCompletedNCT04635800Phase 1
- Optimizing the Treatment Strategy for Age-related Macular DegenerationActive, not recruitingNCT04420923Not applicable
- Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract SurgeryStatus unknownNCT03944070Not applicable
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03844074Phase 3
- CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)CompletedNCT03803631
- ADVM-022 Intravitreal Gene Therapy for Wet AMDCompletedNCT03748784Phase 1
- Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular DegenerationTerminatedNCT03699618
- Ziv-aflibercept Efficacy in Better Regulating AMDCompletedNCT03423823Phase 2
- The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical SettingCompletedNCT03278262
- Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular DegenerationCompletedNCT02944227Phase 4
- Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal VasculopathyStatus unknownNCT02806752Phase 4
- Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in JapanCompletedNCT02541084
- To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.CompletedNCT02540369
- Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMDCompletedNCT02321241
- Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in ItalyCompletedNCT02289924
- Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic TreatmentCompletedNCT02287298
- Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMDCompletedNCT02279537
- Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular DegenerationCompletedNCT02204683Phase 1
- Prophylactic Ranibizumab for Exudative Age-related Macular DegenerationCompletedNCT02140151Phase 1/2
- Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular DegenerationCompletedNCT02060604Phase 4
- Stem Cell Ophthalmology Treatment StudyStatus unknownNCT01920867Not applicable
- Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth FactorCompletedNCT01896284Phase 4
- Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMDCompletedNCT01835067Phase 2/3
- On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)Status unknownNCT01670162Phase 4
- A Population-based Study of Macular Choroidal Neovascularization in a Chinese PopulationCompletedNCT01666821
- Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)CompletedNCT01535950Phase 2
- An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationStatus unknownNCT01521065Phase 2
- Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular DegenerationCompletedNCT01494805Phase 1/2
- Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular DegenerationCompletedNCT01473251Not applicable
- Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in GermanyCompletedNCT01448538
- Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to RanibizumabStatus unknownNCT01249937Phase 2
- OZURDEX in Age Related Macular Degeneration as Adjunct to RanibizumabCompletedNCT01243086Phase 2
- HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular DegenerationTerminatedNCT01189019Phase 2
- Lucentis for Age-related Macular Degeneration Pigment Epithelial DetachmentsCompletedNCT00590694Phase 2/3
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)WithdrawnNCT00557791Phase 3